Hong Yong Peh, W.S. Daniel Tan, Wupeng Liao, W.S. Fred Wong, Pharmacology & Therapeutics, Available online 17 December 2015, ISSN 0163-7258, doi:10.1016/j.pharmthera.2015.12.003.
Modifications to tocotrienols were performed as well: Vatiquinone (EPI-743), structurally similar to α-tocotrienol metabolite α-tocotrienol quinone, was developed for the treatment of Leigh syndrome and other inherited mitochondrial diseases by Edison Pharmaceuticals Inc. Currently, EPI-743 was approved by FDA (United States of America Food and Drug Administration) in July 2014 for the treatment of Leigh syndrome and an ongoing Phase-IIb clinical trial for Friedreich’s ataxia
Saturday, December 19, 2015
Subscribe to:
Posts (Atom)
